

## Human and Mouse ORFeome Collaboration Clones


Distributed through K.K. DNAFORM

### Vector Map: pENTR221

**NAME:** pENTR221  
**RESISTANT MARKER:** Kanamycin resistant; 10 µg/ml  
**SOURCE:** Invitrogen Life Technologies  
**V\_TYPE:** Gateway entry vector  
**SEQUENCING PRIMERS:** M13(-21), M13 reverse

**Note the specific antibiotic to be used with this vector.**  
**Confirm sequencing primer sequences match vector before sequencing.**

#### Map



**POLYLINKER SEQUENCE:**

CGACAAACAACAGATAAAACGAAAGGCCAGTCTTCCGACTGAGCCTTTTC  
 GTTTTTATTTGATGCCTGGCAGTTCCTACTCTCGCGTTAACGCTAGCATG  
 GATGTTTTCCAGTCACGACGTTGTAAAACGACGGCCAGTCTTAAGCTCG  
 GGCCCCAAATAATGATTTTTATTTTACTGATAGTGACCTGTTTCGTTGCAA  
 CAAATTGATGAGCAATGCTTTTTTTATAATGCCAACTTTGTACAAAAAAGC  
 AGGCT-linker-ORF-linker-ACCCAGCTTCTTGTACAAAGTTGGC  
 ATTATAAGAAAGCATTGCTTATCAATTTGTTGCAACGAACAGGTCACTAT  
 CAGTCAAAAATAAAATCATTATTTGCCATCCAGCTGATATCCCCTATAGTG  
 AGTCGTATTACATGGTCATAGCTGTTTCCCTGGCAGCTCTGGCCCCGTGTCT  
 CAAAATCTCTGATGTTACATTGCACAAGATAAAAATATATCATCATGAAC  
 AATAAAACTGCTCTGCTTACATAAACAGTAATACAAGGGGTGTTATGAGCC  
 ATATTCAACGGGAAACGTCGAGGCCGCGATTAAATTCCA

**Sequence:**

1	ACATGTTCTT	TCCTGCGTTA	TCCCCTGATT	CTGTGGATAA	CCGTATTACC	GCCTTTGAGT	60
61	GAGCTGATAC	CGCTCGCCGC	AGCCGAACGA	CCGAGCGCAG	CGAGTCAGTG	AGCGAGGAAG	120
121	CGGAAGAGCG	CCCAATACGC	AAACCGCCTC	TCCCCGCGCG	TTGGCCGATT	CATTAATGCA	180
181	GCTGGCACGA	CAGGTTTTCCC	GACTGGAAAG	CGGGCAGTGA	GCGCAACGCA	ATTAATACGC	240
241	GTACCGCTAG	CCAGGAAGAG	TTTGTAGAAA	CGCAAAAAGG	CCATCCGTCA	GGATGGCCTT	300
301	CTGCTTAGTT	TGATGCCTGG	CAGTTTATGG	CGGGCGTCTT	GCCCCGCCACC	CTCCGGGCCG	360
361	TTGCTTCACA	ACGTTCAAAT	CCGCTCCCAG	CGGATTTGTC	CTACTCAGGA	GAGCGTTCAC	420
421	CGACAAACAA	CAGATAAAAC	GAAAGGCCCA	GTCTTCCGAC	TGAGCCTTTC	GTTTTATTTG	480
481	ATGCCTGGCA	GTTCCCTACT	CTCGCGTTAA	CGCTAGCATG	GATGTTTTTC	CAGTCACGAC	540
541	GTTGTAAAAC	GACGGCCAGT	CTTAAGCTCG	GGCCCCAAAT	AATGATTTTA	TTTTGACTGA	600
601	TAGTGACCTG	TTCGTTGCAA	CAAATTGATG	AGCAATGCTT	TTTTATAATG	CCAACTTTGT	660
661	ACAAAAAAGC	AGGCTACCCA	GCTTCTTGT	ACAAAGTTGG	CATTATAAGA	AAGCATTGCT	720
721	TATCAATTTG	TTGCAACGAA	CAGGTCACCT	TCAGTCAAAA	TAAAATCATT	ATTTGCCATC	780
781	CAGTCGATAT	CCCCATATAGT	GAGTCGTATT	ACATGGTCAT	AGCTGTTTTCC	TGGCAGCTCT	840
841	GGCCCGTGTC	TCAAAATCTC	TGATGTTACA	TTGCACAAGA	TAAAAATATA	TCATCATGAA	900
901	CAATAAAACT	GCTCTGCTTAC	ATAAACAGTA	ATACAAGGGG	TGTTATGAGC	CATATTCAAC	960
961	GGGAAACGTC	GAGGCCGCGA	TTAAATTCCA	ACATGGATGC	TGATTTATAT	GGGTATAAAT	1020
1021	GGGCTCGCGA	TAATGTCGGG	CAATCAGGTG	CGACAATCTA	TCGCTTGTAT	GGGAAGCCCG	1080
1081	ATGCGCCAGA	GTTGTTTTCTG	AAACATGGCA	AAGGTAGCGT	TGCCAATGAT	GTTACAGATG	1140
1141	AGATGGTCAG	ACTAAACTGG	CTGACGGAAT	TTATGCCTCT	TCCGACCATC	AAGCATTTTA	1200
1201	TCCGTACTCC	TGATGATGCA	TGTTACTCA	CCACTGCGAT	CCCCGGAAAA	ACAGCATTCC	1260
1261	AGGTATTAGA	AGAATATCCT	GATTCAGGTG	AAAATATTGT	TGATGCGCTG	GCAGTGTTC	1320
1321	TGCGCCGGTT	GCATTCGATT	CCTGTTTGT	ATTGTCCTTT	TAACAGCGAT	CGCGTATTT	1380
1381	GTCTCGCTCA	GGCGCAATCA	CGAATGAATA	ACGGTTTGGT	TGATGCGAGT	GATTTTGATG	1440
1441	ACGAGCGTAA	TGGCTGGCCT	GTTGAACAAG	TCTGGAAAGA	AATGCATAAA	CTTTTGCCAT	1500
1501	TCTCACC GGA	TTCAGTCGTC	ACTCATGGTG	ATTTCTCACT	TGATAACCTT	ATTTTTGACG	1560
1561	AGGGGAAATT	AATAGGTTGT	ATTGATGTTG	GACGAGTCGG	AATCGCAGAC	CGATACCAGG	1620
1621	ATCTTGCCAT	CCTATGGAAC	TGCCTCGGTG	AGTTTTCTCC	TTCATTACAG	AAACGGCTTT	1680
1681	TTCAAAAATA	TGGTATTGAT	AATCCTGATA	TGAATAAATT	GCAGTTTCAT	TTGATGCTCG	1740
1741	ATGAGTTTTT	CTAATCAGAA	TTGGTTAATT	GGTTGTAACA	CTGGCAGAGC	ATTACGCTGA	1800
1801	CTTGACGGGA	CGGCGCAAGC	TCATGACCAA	AATCCCTTAA	CGTGAGTTAC	GCGTCGTTCC	1860
1861	ACTGAGCGTC	AGACCCCGTA	GAAAAGATCA	AAGGATCTTC	TTGAGATCCT	TTTTTTCTGC	1920
1921	GCGTAATCTG	CTGCTTGCAA	ACAAAAA AAC	CACCGCTACC	AGCGGTGGTT	TGTTTGCCGG	1980
1981	ATCAAGAGCT	ACCAACTCTT	TTTCCGAAGG	TAAGTGGCTT	CAGCAGAGCG	CAGATACCAA	2040
2041	ATACTGTCCT	TCTAGTGTAG	CCGTAGTTAG	GCCACCACTT	CAAGAACTCT	GTAGCACCGC	2100
2101	CTACATACCT	CGCTCTGCTA	ATCCTGTTAC	CAGTGGCTGC	TGCCAGTGGC	GATAAGTCGT	2160
2161	GTCTTACCGG	GTTGGACTCA	AGACGATAGT	TACCGGATAA	GGCGCAGCGG	TCGGGCTGAA	2220
2221	CGGGGGGTTT	GTGCACACAG	CCCAGCTTGG	AGCGAACGAC	CTACACCGAA	CTGAGATACC	2280
2281	TACAGCGTGA	GCATTGAGAA	AGCGCCACGC	TTCCCGAAGG	GAGAAAGGCG	GACAGGTATC	2340
2341	CGGTAAGCGG	CAGGGTCGGA	ACAGGAGAGC	GCACGAGGGA	GCTTCCAGGG	GGAAACGCCT	2400
2401	GGTATCTTTA	TAGTCCTGTC	GGGTTTTCGCC	ACCTCTGACT	TGAGCGTCGA	TTTTTTGTGAT	2460
2461	GCTCGTCAGG	GGGGCGGAGC	CTATGGAAAA	ACGCCAGCAA	CGCGGCCTTT	TTACGGTTCC	2520
2521	TGGCCTTTTG	CTGGCCTTTT	GCTC				2544

All ORF clones are provided in Entry Vectors for the Invitrogen Gateway® cloning system. Invitrogen offers a whole range of Destination Vectors for a wide range of applications. Refer to the homepage of Invitrogen for further information on the Gateway® cloning system and related Invitrogen products at:

<http://www.invitrogen.com/content.cfm?pageid=4072>

For further information on the ORFeome Collaboration, visit their homepage at <http://www.orfeomecollaboration.org/html/index.shtml>.

For further technical information visit our homepage at: <http://www.dnaform.jp> or contact us under: [techinfo@dnaform.jp](mailto:techinfo@dnaform.jp).

### **Contact Address**

K.K. DNAFORM – *Precision Gene Technologies*  
Leading Venture Plaza-2  
75-1, Ono-cho, Tsurumi-ku, Yokohama City  
Kanagawa 230-0046  
Japan

Tel: +81-(0)45-510-0607  
Fax: +81-(0)45-510-0608  
e-mail: [techinfo@dnaform.jp](mailto:techinfo@dnaform.jp)  
Homepage: <http://www.dnaform.jp>